A Multi-Center, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland—First Results

A Multi-Center, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland—First Results

Tuberculosis vaccines (Bacillus Calmette-Guérin, BCG) were introduced 100 years ago and are still recommended by the World Health Organization to prevent the disease. Studies have shown that BCG vaccination can stimulate non-specific immune responses and reduce the incidence of certain diseases. At...

Full description

Bibliographic Details
Main Authors: Hanna Czajka, Paweł Zapolnik, Łukasz Krzych, Wojciech Kmiecik, Lidia Stopyra, Anna Nowakowska, Teresa Jackowska, Dorota Darmochwał-Kolarz, Henryk Szymański, Igor Radziewicz-Winnicki, Artur Mazur
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Vaccines
Subjects:
COVID-19
BCG
vaccines
clinical trial
SARS-CoV-2
health care
Online Access:https://www.mdpi.com/2076-393X/10/2/314

Internet

https://www.mdpi.com/2076-393X/10/2/314

Similar Items